Compounded vs. Brand-Name GLP-1: Safety, Quality, and How to Choose

May 2026  |  BetterNewLives.com

Millions of people are now taking compounded semaglutide or tirzepatide — medications produced by compounding pharmacies rather than Novo Nordisk or Eli Lilly. For most of them, the question is the same: Is this safe? Is this legal? Is it actually the same thing? The honest answers are nuanced, and understanding them properly is genuinely important.

What "Compounded" Actually Means

A compounding pharmacy takes pharmaceutical-grade active ingredients and formulates them into a specific dosage form — in this case, an injectable solution — for a specific patient under a valid prescription. Compounding has a long and legitimate history in pharmacy: it's how patients get custom doses, allergen-free formulations, and medications not available commercially.

What compounding is not: it is not manufacturing. Compounded products are not FDA-approved finished drug products. They are not subject to the same pre-market review, clinical testing, or batch-release standards as brand-name pharmaceuticals. This distinction matters — and it means compounded GLP-1 medications are not simply generic Ozempic or Mounjaro.

The Critical Distinction: 503A vs. 503B Pharmacies

Not all compounding pharmacies are equal. The difference between a 503A and 503B facility is one of the most important things to understand when evaluating a telehealth program.

503A: Traditional compounding pharmacy

503A pharmacies are licensed by their state pharmacy board and can produce patient-specific compounded medications. They are not registered with the FDA and do not operate under FDA cGMP standards. Quality control practices vary widely. Some 503A pharmacies have excellent internal standards; others do not. There is no systematic federal oversight to distinguish them. When compounding sterile injectables (as GLP-1 medications are), the stakes of poor quality control are meaningfully higher than for oral medications.

503B: FDA-registered outsourcing facility

503B outsourcing facilities are registered directly with the FDA and operate under current Good Manufacturing Practice (cGMP) standards — the same quality framework governing Pfizer and Eli Lilly's manufacturing plants. They are subject to regular FDA inspections, must maintain detailed batch records, must report adverse events, and can only produce medications on the FDA shortage list. A 503B facility producing semaglutide vials is operating under a genuinely rigorous quality framework.

The FDA Shortage Framework — And Why It's Changing

Federal law generally prohibits compounding pharmacies from producing copies of commercially available FDA-approved drugs. However, an exception applies when the FDA places a drug on its shortage list — at that point, licensed compounders can legally produce that drug.

The FDA added semaglutide to its drug shortage list in 2022 and tirzepatide in late 2023, driven by surging demand far outpacing Novo Nordisk's and Eli Lilly's manufacturing capacity. This opened the door to the compounded GLP-1 market that now serves millions of patients.

As of 2026, the FDA has been updating its shortage list status for both drugs as supply has improved. The agency has issued guidance making clear that once a shortage is resolved, the legal basis for compounding that specific drug is significantly curtailed. This regulatory landscape is actively shifting — patients on compounded programs should monitor FDA shortage list updates, as a formal shortage resolution could affect their program's legal standing and the compounding pharmacy's ability to continue supplying the medication.

How to Evaluate a Compounding Pharmacy

If you are using or considering a telehealth program with compounded GLP-1 medication, here are the questions to ask and the signals to look for:

• Is the pharmacy 503B registered with the FDA? (Ask for their FDA registration number and verify at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities)
• Does the pharmacy provide a Certificate of Analysis (COA) for each batch of medication?
• Is the COA from a named, independent third-party testing laboratory?
• Does the COA show purity, potency, sterility, and endotoxin testing results?
• Does the pharmacy have PCAB (Pharmacy Compounding Accreditation Board) accreditation?
• Is the pharmacy's physical address and state license publicly verifiable?
• No COA available or COA from an unnamed lab
• Cannot confirm 503B status or deflects the question
• Prices dramatically lower than any other program (may indicate corner-cutting)
• No prescription required to purchase
• Claims their product is "equivalent to" or "just like" Ozempic/Mounjaro

When Brand-Name Is Worth the Premium

There are genuine situations where the brand-name product is clearly preferable, despite the higher cost:

• You qualify for savings cards or patient assistance — If the Lilly or Novo Nordisk programs bring your cost to $25–$99/month, brand-name is almost always the better choice at that price point.
• You have a complex medical history — For patients with significant comorbidities, multiple medications, or a history of adverse drug reactions, the standardized manufacturing and established pharmacovigilance of brand-name products provides a safety margin worth paying for.
• You want the autoinjector pen — Brand-name products come in pre-filled, pre-calibrated pens that many patients find easier and more reliably dosed than vial-and-syringe injection.
• Regulatory uncertainty is a concern — If you're worried about the FDA's evolving compounding stance affecting your access mid-treatment, brand-name provides more stable long-term access.

When Compounded Is a Reasonable Choice

• You don't qualify for savings cards and can't access brand-name at a manageable cost
• Your program uses a verified 503B compounding facility
• You have reviewed the batch COA for your medication
• You are accessing the medication through a licensed prescriber with proper oversight
• You understand the regulatory framework and are monitoring shortage list status